Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice

Digestive and Liver Disease

Volumn 47, Issue 3, 2015, Pages 233-241

  Cento, Valeria ^a   Tontodonati, Monica ^b,c   Di Maio, Velia Chiara ^a   Bellocchi, Maria Concetta ^a   Valenti, Fabrizio ^d   Manunta, Alessandra ^e   Fortuna, Serena ^f   Armenia, Daniele ^a   Carioti, Luca ^a   Antonucci, Francesco Paolo ^a   Bertoli, Ada ^g   Trave, Francesca ^b   Cacciatore, Pierluigi ^b   Angelico, Mario ^g   Navarra, Pierluigi ^f   Neumann, Avidan U ^h   Vecchiet, Jacopo ^c   Parruti, Giustino ^b   Babudieri, Sergio ^e   Perno, Carlo Federico ^a,g   Ceccherini Silberstein, Francesca ^a   more..

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b Pescara General Hospital   (Italy)

^c Infectious Diseases Clinic   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e UNIVERSITY OF SASSARI   (Italy)

^f FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^g TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^h BAR ILAN UNIVERSITY   (Israel)

Author keywords

Drug resistance; Mathematical modelling; Protease inhibitors; Viral kinetic

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PEGINTERFERON ALPHA; RIBAVIRIN; TELAPREVIR; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; OLIGOPEPTIDE; PROTEINASE INHIBITOR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TREATMENT FAILURE; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; MALE; MOLECULAR DYNAMICS; MOLECULAR EVOLUTION; NONSENSE MEDIATED MRNA DECAY; PRIORITY JOURNAL; PYROSEQUENCING; SEQUENCE ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD; VIRUS REPLICATION; AGED; ANTIVIRAL RESISTANCE; DRUG COMBINATION; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; MUTATION; RNA STABILITY; STATISTICAL MODEL;

AGED; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LINEAR MODELS; MALE; MIDDLE AGED; MUTATION; OLIGOPEPTIDES; PROTEASE INHIBITORS; RIBAVIRIN; RNA STABILITY; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

EID: 84924068904     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2014.12.004     Document Type: Article

References (22)

1. Bacon B.R., Gordon S.C., Lawitz E., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. New England Journal of Medicine 2011, 364:1207-1217.
2. Jacobson I.M., McHutchison J.G., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. New England Journal of Medicine 2011, 364:2405-2416.
3. Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. New England Journal of Medicine 2011, 364:1195-1206.
4. Zeuzem S., Andreone P., Pol S., et al. Telaprevir for retreatment of HCV infection. New England Journal of Medicine 2011, 364:2417-2428.
5. Pawlotsky J.M. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011, 53:1742-1751.
6. Soriano V., Perelson A.S., Zoulim F. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?. Journal of Antimicrobial Chemotherapy 2008, 62:1-4.
7. Ribeiro R.M., Li H., Wang S., et al. Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathogens 2012, 8:e1002881.
8. Martell M., Esteban J.I., Quer J., et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. Journal of Virology 1992, 66:3225-3229.
9. Rong L., Dahari H., Ribeiro R.M., et al. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Science Translational Medicine 2010, 2:30ra32.
10. Guedj J., Perelson A.S. Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology 2011, 53:1801-1808.
11. Neumann A.U., Lam N.P., Dahari H., et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282:103-107.
12. Rosen H.R., Ribeiro R.R., Weinberger L., et al. Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy. Journal of Hepatology 2002, 37:124-130.
13. Dixit N.M., Layden-Almer J.E., Layden T.J., et al. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004, 432:922-924.
14. Chatterjee A., Guedj J., Perelson A.S. Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?. Antiviral Therapy 2012, 17(Pt B):1171-1182.
15. European Medicines Agency (EMA) Incivek (telaprevir) Film Coated Tablets 2011 May 1, EU Prescibing Information.
16. Guedj J., Neumann A.U. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics. Journal of Theoretical Biology 2010, 267:330-340.
17. Cento V., Mirabelli C., Salpini R., et al. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS ONE 2012, 7:e39652.
18. Zagordi O., Bhattacharya A., Eriksson N., et al. ShoRAH: estimating the genetic diversity of a mixed sample from next-generation sequencing data. BMC Bioinformatics 2011, 12:119.
19. Tamura K., Peterson D., Peterson N., et al. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Molecular Biology and Evolution 2011, 28:2731-2739.
20. Nasu A., Marusawa H., Ueda Y., et al. Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing. PLoS ONE 2011, 6:e24907.
21. Cento V., Di Maio V.C., Di Paolo D., et al. NS3-resistance in advanced HCV patients treated with BOC/TRV-based therapy: impact on virological failure of baseline and early time points. The Liver Meeting 2013, AASLD Abstracts. Hepatology 2013, 58(Suppl. 1):1960.
22. Taylor N., Haschke-Becher E., Greil R., et al. Performance characteristics of the COBAS Ampliprep/COBAS TaqMan v2.0 and the Abbott RealTime hepatitis C assays - implications for response-guided therapy in genotype 1 infections. Antiviral Therapy 2014, 19:449-454.